IN THE CLAIMS

1. (Cancelled)

2. (Previously Amended) The pharmaceutical composition according to Claim 43 in which said alkalizing agent includes an alkaline earth metal .

3. (Previously Amended) The pharmaceutical composition according to Claim 43 wherein the dry-granulated composition, after storage at 40°C and 75% relative humidity for 4 weeks, contains not more than about 2% total impurities and/or degradants based on area percent of drug related HPLC peaks.

4. (Previously Amended) The pharmaceutical composition according to Claim 43 wherein the composition contains not more than about 2% atorvastatin lactone based on area percent of HPLC peaks.

5. (Previously Amended) The pharmaceutical composition according to Claim 43 wherein the composition is used in the formation of a solid unit dosage form.

6. (Original) The pharmaceutical composition according to Claim 5 wherein the unit dosage form is selected from the group consisting of a tablet and a capsule.

7. (Previously Amended) The pharmaceutical composition according to Claim 43 wherein the atorvastatin contains at least some partially or completely disordered form of atorvastatin or a pharmaceutically acceptable salt thereof.

8. (Cancelled)

9. (Cancelled)

10. (Cancelled)

11. (Previously Amended) The pharmaceutical composition according to Claim 17 wherein said diluent has a mean particle size between about 20 and 200 μm.

12. (Previously Amended) The pharmaceutical composition according to Claim 17 wherein said diluent has a mean particle size between 40 and 150 μm.

13. (Previously Amended) The pharmaceutical composition according to Claim 43 wherein said composition shows a granulation factor of between about 0.4 and 1.0.

14. (Previously Amended) The pharmaceutical composition according to Claim 43 wherein said composition shows a granulation factor of between about 0.5 and 1.0.

15. (Previously Amended) The pharmaceutical composition according to Claim 43 wherein said composition shows a granulation factor of between about 0.6 and 1.0.

16. (Cancelled.)

17. (Currently Amended) The pharmaceutical composition according to Claim 43 in which at least about 50% (w:w) of said diluent is composed an ingredient selected from the group consisting of microcrystalline cellulose, lactose, sucrose, and xylitol, ~~and calcium phosphate dibasic.~~

Claims 18-42 (Cancelled.)

43. (Currently Amended) A dry granulated pharmaceutical composition comprising:

a) from 1-40 w/w % of atrovastatin,

b) at least 40 wt% of a diluent in which said diluent contains at least one component selected from the group consisting of calcium phosphate, calcium

sulfate, carboxymethylcellulose calcium, cellulose, cellulose acetate, dextrates, dextrin, dextrose, fructose, glyceryl palmitostearate, hydrogenated vegetable oil, kaolin, lactitol, lactose, magnesium carbonate, magnesium oxide, maltitol, maltodextrin, maltose, polymethacrylates, pregelatinized starch, silicified microcrystalline cellulose, sodium chloride, sorbitol, starch, sucrose, xylitol and talc, and,

c) less than 5 w/w% of an alkalizing agent.

44. (Previously Added) The pharmaceutical composition according to claim 43 in which said atorvastatin is amorphous.

45. (Previously Added) The pharmaceutical composition according to claim 43 in which said alkalizing agent is present in the quantity of less than 3 w/w%.

46. (Previously Added) The pharmaceutical composition according to claim 43 in which said alkalizing agent is present in the quantity of less than 2 w/w%.

47. (New) The pharmaceutical composition according to Claim 43 in which at least 60% (w:w) of said diluent is composed an ingredient selected from the group consisting of microcrystalline cellulose, lactose, sucrose, and xylitol.

48. (New) The pharmaceutical composition according to Claim 43 in which at least 70% (w:w) of said diluent is composed an ingredient selected from the group consisting of microcrystalline cellulose, lactose, sucrose, and xylitol.

49. (New Claim) The pharmaceutical composition according to Claim 48 wherein said diluent has a mean particle size between 40 and 150 μm.

50. (New Claim) The pharmaceutical composition according to Claim 49 wherein said composition shows a granulation factor of between about 0.6 and 1.0.

51. (New Claim) A dry granulated pharmaceutical composition comprising:

a) from 1-40 w/w % of atrovastatin,

b) at least 60 wt% of a diluent selected from the group consisting of microcrystalline cellulose, lactose, sucrose, and xylitol, and;

c) less than 2 w/w% of an alkalizing agent.

52. (New Claim) The pharmaceutical composition according to Claim 51 wherein said diluent has a mean particle size between 40 and 150 μm.

53. (New Claim) The pharmaceutical composition according to Claim 52 wherein said composition shows a granulation factor of between about 0.6 and 1.0.